CRISPR-based lateral flow (SHERLOCK/DETECTR)

01Overview and value chain#

Markers EC: FDA IVD and emergency-use review pathways + EU IVDR 2017/746 + NMPA emergency approvals | OECD: Biotechnology and health | Regulator: FDA (USA), EMA (EU), NMPA (China)

CRISPR diagnostics repurpose the defense machinery of bacteria into a test: a guide RNA directs a Cas12 or Cas13 enzyme to a target sequence, and on finding it the enzyme shreds any single-stranded reporter in the vicinity — a collateral-cleavage burst that converts molecular recognition into a visible signal on a paper strip. The architecture solves the two problems that kept molecular diagnostics out of point-of-care: it needs no thermocycler (isothermal amplification feeds the CRISPR step) and no instrument (lateral flow reads the result by eye). SHERLOCK (Cas13) and DETECTR (Cas12) — the platform names the field inherited from its founding papers — reached regulated products fast: Sherlock Biosciences took the first CRISPR-based FDA Emergency Use Authorization for SARS-CoV-2 in May 2020 and now runs an ISO 13485-certified manufacturing facility in Swavesey, UK sized for 5 million diagnostic devices annually; Mammoth Biosciences, with $375 million raised, holds a FDA EUA for its DETECTR BOOST SARS-CoV-2 Reagent Kit and runs high-throughput capacity of 1,500 tests per 8-hour shift in CLIA laboratories; and BGI industrialized the readout-adjacent layer at population scale — 3.705 billion CNY revenue for fiscal 2025, NMPA emergency approvals for its COVID-19 detection kits, EU CE certification for nucleic-acid and antigen kits, and an Addis Ababa factory producing 10 million test kits a year.

Key directions of CRISPR-based lateral flow diagnostics:

1. Collateral-cleavage signal chemistry (Cas12/Cas13 Reporters): guide-programmed recognition amplified into a shredded-reporter signal — the core reaction SHERLOCK and DETECTR turned into platform families.
2. Emergency-use to IVD conversion (Regulated Products): first CRISPR-based FDA EUA (Sherlock Biosciences, SARS-CoV-2, May 2020), DETECTR BOOST EUA (Mammoth, 2022), and the post-emergency path to ordinary IVD review under FDA and IVDR regimes.
3. Instrument-free point-of-care format (Paper-Strip Readout): lateral flow strips that read by eye, fed by isothermal amplification — capacity of 1,500 tests per 8-hour shift in CLIA laboratories shows the operational form.
4. Population-scale manufacturing (Million-Kit Plants): ISO 13485-certified lines sized at 5 million devices annually (Sherlock’s Swavesey facility) and a 10-million-kits-per-year factory in Addis Ababa (BGI) — manufacturing as the deployment bottleneck.

Sectoral value chain#

[guide RNA design] ──> [reaction formulation] ──> [amplification + CRISPR detection]
                                                                      │
                                                          (reporter cleavage signal)
                                                                      │
                                                                      ▼
[clinical decision] <── [distribution, cold chain] <── [strip manufacturing, QC]

Value chain levels#

Cross-cutting technologies of the sector:

• Isothermal amplification (LAMP/RPA): the thermocycler-free engine that feeds the CRISPR detection step.
• Lyophilized reagent formats (Ambient-Stable Kits): the packaging that makes strip diagnostics survivable outside cold chains.
• Nucleic-acid extraction at point of care (Sample Prep): the unglamorous front end that decides field performance.

02US#

The US invented the platform families and hosts both CRISPR-diagnostics pure-plays; the FDA’s emergency-use pathway is what carried their first products to market.

Platform founding labs, EUA products, venture scale#

• Sherlock Biosciences (Cambridge, MA): the SHERLOCK platform company — first CRISPR-based FDA Emergency Use Authorization for SARS-CoV-2 (May 2020), an ISO 13485-certified manufacturing facility in Swavesey, UK sized for 5 million diagnostic devices annually, with revenue primarily grant-funded as of December 2024.
• Mammoth Biosciences (Brisbane, CA): the DETECTR platform company — $375 million raised to date, FDA EUA for DETECTR BOOST SARS-CoV-2 Reagent Kit received in 2022, high-throughput capacity of 1,500 tests per 8-hour shift, tests performed in high-complexity CLIA laboratories, with a planned Abu Dhabi advanced-therapy manufacturing facility.
• FDA emergency pathway as launch rail: both companies’ first regulated products shipped under EUA — the same pathway that later IVD conversions must graduate from.

03CN#

China industrialized the readout-adjacent layer at population scale; BGI’s testing infrastructure shows what manufacturing depth CRISPR diagnostics will inherit as the platform converts to ordinary IVD products.

BGI’s testing manufacturing, NMPA emergency approvals, kit export#

• BGI (Shenzhen): 3.705 billion CNY revenue for fiscal 2025, NMPA emergency approval for COVID-19 detection kits and the DNBSEQ-T7 sequencing system, EU CE certification for monkeypox nucleic-acid and COVID-19 antigen kits.
• Manufacturing at population scale: a COVID-19 testing kit factory in Addis Ababa, Ethiopia with annual output of 10 million kits — the export form of Chinese diagnostics manufacturing that CRISPR formats will ride.
• NMPA emergency track: China’s emergency-approval route moved detection kits to market at pandemic speed — the regulatory channel CRISPR-based products would use for the next pathogen.

04EU#

Europe contributes the IVDR certification regime that all post-emergency CRISPR diagnostics must clear for European deployment, and hosts one leg of Sherlock’s manufacturing.

IVDR certification, UK manufacturing site, post-emergency conversion#

• Sherlock’s Swavesey facility (UK): an ISO 13485-certified manufacturing site at Buckingway Business Park — approximately 45 employees as of 2023 — the European manufacturing leg of the platform’s first mover.
• IVDR as the European gate: emergency-era products must convert to certified IVDs under IVDR 2017/746 for European deployment — the same evidentiary conversion the cfDNA field already ran.
• CE marking as export currency: BGI’s CE-certified monkeypox and COVID-19 kits show the marking’s reach beyond Europe — CE-marked kits flow through markets the IVDR does not govern.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack is three layers — recognition, amplification, readout — and its innovations are about collapsing them into a strip a nurse can run.

1. Collateral-cleavage detection chemistry (Cas Reporters):
   • Cas12/Cas13 enzymes activated by target binding shred fluorescent or lateral-flow reporters — molecular specificity becomes a visible line.
   • case: SHERLOCK (Cas13) and DETECTR (Cas12) platform families, both carrying FDA EUAs for SARS-CoV-2.
2. Isothermal amplification feeding CRISPR (Thermocycler-Free):
   • LAMP/RPA pre-amplification runs at constant temperature, removing the instrument that separated molecular tests from point of care.
   • case: Mammoth’s 1,500-tests-per-8-hour-shift high-throughput system in CLIA laboratories.
3. Manufacturing-grade strip production (ISO 13485 Lines):
   • diagnostics become logistics: lyophilized chemistry on strips manufactured and released like any regulated device.
   • case: Sherlock’s Swavesey facility sized for 5 million devices annually; BGI’s Addis Ababa factory at 10 million kits per year.

07Value chains and production pipelines#

Industrial pipeline of a CRISPR lateral flow test lot (ISO 13485 device-manufacturing regime)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Guide and assay design │ ───> │ 2. Reagent manufacture    │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. QC and lot release     │ <─── │ 3. Strip manufacture,     │
│                           │      │ lyophilization            │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Distribution           │ ───> │ 6. Point-of-care run      │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Guide and assay design

Pathogen genomes are screened for target sequences the guide RNA can claim uniquely — design is where false positives are prevented before any chemistry exists.

Stage 2: Reagent manufacture

Cas enzymes, guide RNAs, reporters and amplification reagents are produced under device-grade quality — the input chemistry every strip inherits.

Stage 3: Strip manufacture and lyophilization

Strips are manufactured and the reaction is dried onto them under ISO 13485 — capacity lines at 5 million devices per year (Swavesey) are sized for national campaigns, not laboratory menus.

Stage 4: QC and lot release

Lots are released against performance standards — the step that converts a laboratory reaction into a regulated diagnostic a regulator can trace.

Stage 5: Distribution

Kits ship at ambient or cold-chain temperature depending on format; BGI’s Addis Ababa factory shows the localization form distribution takes at population scale.

Stage 6: Point-of-care run

Extraction, isothermal amplification and strip read happen where the patient is — 1,500 tests per 8-hour shift per CLIA site is the operational throughput the format reaches.